U.S. FDA staff flags no new safety concerns for Biogen's ALS drug


March 20 (Reuters) - The U.S. Food and Drug Administration's staff reviewers on Monday did not raise any new safety concerns about Biogen Inc's BIIB.O experimental drug for treating a rare type of amyotrophic lateral sclerosis, also known as Lou Gehrig's disease.

(Reporting by Raghav Mahobe and Bhanvi Satija in Bengaluru; Editing by Krishna Chandra Eluri)

((; Outside U.S. +91 9873062788;))

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


More Related Articles

Sign up for Smart Investing to get the latest news, strategies and tips to help you invest smarter.